What you'll learn
Key ideas from Bad Blood
These ideas compress the book's argument without treating the author's view as settled fact. Use them as an orientation before reading the full work or listening in Wiseley.
Family and Stanford networks, pharmaceutical economics, and prominent validators helped turn an unproven prototype into a credible investment story.
Theranos’s tiny-sample microfluidic design could not reliably coordinate diluted blood, valves, channels, and chemistry.
Walgreens’s Project Beta turned Theranos’s promise into a pilot, cartridge-purchase exposure, and loan before independent verification was secured.
Deadline pressure led Theranos to replace unfinished devices with a modified Siemens analyzer and an unapproved double-dilution process.
Tyler Shultz and Erika Cheung resigned after raising patient-care and laboratory concerns, while management answered with pressure, secrecy, and confidentiality demands.
Patient cases, expert review, repeat testing, and documents converged on unreliable results and hidden workarounds.
CMS found immediate patient-safety danger in unreliable testing and widespread laboratory control failures.
How Bad Blood builds its case
Follow how the book develops its argument. Each note is a brief orientation, not a replacement for the chapter.
Promise Before Proof
Bad Blood begins with a problem of sequence: Theranos’s promise became credible before its device had earned that credibility. John Carreyrou bases the account on hundreds of interviews, including more than sixty former employees, plus documents, emails, and legal records.
The Machine Beneath the Brand
The first device failed for a reason deeper than a bad component: Theranos had made the blood sample too small for the system it designed. Ed Ku found the inherited prototype was largely a mock-up.
Power, Secrecy, and Sunny
An early intellectual-property threat to Theranos grew out of a family relationship. The Holmeses and Fuiszes had been neighbors in Washington, and their children shared birthdays and family routines.
The Retail Bet
By 2010, Theranos needed retailers to build a future around a device that was still difficult to inspect. Walgreens and Safeway accepted the promise, then made commitments that made retreat costly.
When Oversight Arrived
Safeway’s employee clinic was meant to test whether Theranos could turn its retail promise into a working service. Safeway had remodeled more than half of its 1,700 stores and spent $350 million on wellness centers, expecting blood testing to repay the investment.
Manufacturing the Myth
By this stage, secrecy had become a liability. People with scientific authority could ask whether Theranos’s devices worked, while the company’s internal structure made those questions harder to answer.
The Launch That Should Not Happen
By twenty thirteen, Theranos faced a choice. It could wait for an unfinished platform, or honor a Walgreens deadline while its relationship with Safeway deteriorated.
Evidence, Dissent, and Fame
Once live Walgreens operations began, Theranos’s promise had to survive contact with records and specimens. Tyler Shultz had joined inspired by Holmes’s vision of painless, early diagnosis.
The Tip Becomes a Case
The evidentiary turning point begins with a private moral crisis, not a public revelation. While Theranos projected celebrity and prosperity, laboratory director Alan Beam was losing faith.
The Counterattack and the Waiting
By mid-2015, the Wall Street Journal was testing its investigation against Theranos’s response. The company did not answer its central questions openly.
Collapse, Consequence, and Meaning
On October 15, 2015, the Wall Street Journal published the exposé that turned Theranos from a celebrated promise into a public controversy. Before publication, Holmes tried to use Rupert Murdoch’s position as the Journal’s largest investor and the owner of its parent company.
